This Week
The Developments
Final rule
CMS finalizes a scaled-down GLOBE drug payment model for Medicare Part B
Announced Sept 30, 2026; Federal Register Oct 2; begins Jan 1, 2027
What changed
CMS finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) model, a mandatory Medicare Part B model that benchmarks payment to international prices. Performance runs through March 31, 2032, and the model covers roughly a quarter of beneficiaries. Exclusions include orphan-only drugs, plasma-derived products, and certain cell and gene therapies. Law-firm analysis of the final rule reports projected savings falling from about $11.9 billion in the proposal to about $440 million.
Why it matters
A mandatory international-reference model was the administration's flagship drug-price lever. The final design reaches far fewer drugs and beneficiaries than proposed, so the affordability effect for patients and for Medicare is likely small compared with the headline.
Warrants deeper follow-up. Compare the proposed and final scope drug by drug, and track which manufacturers obtain waivers.
Sources
Background from our research
Storylines
Announced
Medicare Advantage 2027: lower average premiums, thinner benefits
CMS announcement Sept 28, 2026; open enrollment Oct 15 – Dec 7, 2026
What changed
CMS reported the average Medicare Advantage premium falling from $14.37 to $12.00 for 2027, with about 34 million enrollees (47.4% of eligible beneficiaries). Trade reporting says insurers are trimming dental and Part B premium giveback benefits and expect an enrollment drop of roughly 6%, which CMS disputes.
Why it matters
Lower headline premiums can coexist with weaker coverage. Benefit reductions shift costs to enrollees at the moment they choose plans, and the dispute over the enrollment forecast shows how much of this remains projection.
Warrants deeper follow-up. Compare plan-level benefit changes to the CMS averages once plan data is public.
Sources
Background from our research
Storylines
Litigation
Appeals court hears challenge to Medicare Advantage RADV audit rule
Argument reported Oct 5, 2026; district court ruling Sept 2025
What changed
The Fifth Circuit heard HHS's appeal in Humana v. Kennedy. A district court invalidated the risk-adjustment data validation (RADV) rule in September 2025, and HHS appealed that November. STAT reports the appellate panel appeared skeptical of the government's position. No decision has issued.
Why it matters
RADV audits are the main tool for recovering overpayments tied to inflated diagnosis coding in Medicare Advantage. A loss for HHS would weaken accountability for the program's largest payment-integrity risk.
Warrants deeper follow-up. Watch for the opinion and any HHS response on extrapolation methodology.
Sources
Background from our research
Storylines
Final rule
Five governors ask HHS to delay Medicaid work requirements
Letter reported Oct 2, 2026; interim final rule June 1, 2026; state deadline Jan 1, 2027
What changed
Governors Kotek (OR), Newsom (CA), Mills (ME), Lujan Grisham (NM), and Spanberger (VA) asked HHS to delay the January 1, 2027 compliance date and set a realistic timeline. They say CMS's interim final rule goes beyond the statute, including stricter proof for medically frail people. No HHS response was reported. More than two dozen states are suing over the rule, and a judge has let it remain in effect for now. Nebraska, which began implementing in May, has reported many denials and disenrollments tied to verification problems.
Why it matters
The requirements, enacted in the 2025 reconciliation law, apply to roughly 21 million people covered through ACA expansion. Administrative verification failures, not just ineligibility, can drive coverage loss.
Warrants deeper follow-up. Track Nebraska's disenrollment data and any court ruling before January 1.
Sources
Background from our research
Storylines
Enacted
Federal Medicaid eligibility narrows for refugees, asylees, and parolees
Effective Oct 1, 2026
What changed
Under section 71109 of Public Law 119-21, federally funded full Medicaid and CHIP eligibility narrowed on October 1 to citizens, lawful permanent residents, Cuban and Haitian entrants, and Compact of Free Association residents. Refugees, asylees, and parolees may lose coverage depending on status. Emergency Medicaid remains available, and states can keep federally funded coverage for lawfully residing children and pregnant people under the CHIPRA 214 option. Undocumented immigrants were already ineligible for non-emergency federal Medicaid.
Why it matters
This is enacted law now taking effect, not a proposal. It is narrower than some coverage claims suggest, but it removes federal coverage from groups with documented health needs.
Sources
Background from our research
Storylines
Final rule
Federal agencies finalize insurer price-transparency overhaul
Issued Oct 5, 2026; prescription drug file schema Dec 2027
What changed
CMS, Labor, and Treasury finalized revised Transparency in Coverage rules. They require quarterly reporting and executive certification of accuracy, lower the out-of-network reporting threshold from 20 to 11 claims, and set a new prescription drug file schema for December 2027. The agencies estimate about $175 million in annual savings and about $400 million in one-time costs.
Why it matters
Disclosure only helps patients if the data is accurate and usable. Certification and quarterly updates address accuracy, but the estimated savings are small relative to national spending.
Sources
Background from our research
Storylines
Announced
ACA premiums rise again; White House announces one-time $90 Medicare payment
KFF analysis and White House fact sheet, early Oct 2026
What changed
KFF reports the enhanced ACA premium tax credits expired at the end of 2025, and the median proposed 2027 marketplace premium increase is about 15%. Separately, the White House announced a one-time $90 payment to roughly 20 million Part B enrollees, funded from a $2 billion Medicare Improvement Fund. Reporting found no statute cited for the payment; an outside expert said the administration has broad discretion.
Why it matters
A one-time payment is small against rising premiums, and the legal basis has not been laid out. Both items bear on whether coverage stays affordable without a lasting policy fix.
Warrants deeper follow-up. Identify the statutory authority for the payment and how the Improvement Fund is otherwise obligated.
Sources
Background from our research
Storylines
Announced
PBM market share grows; HRSA approves 340B rebate pilot
AMA analysis Sept 29, 2026; HRSA pilot reported Oct 1; starts Jan 1, 2027
What changed
An AMA analysis, as reported by Fierce Healthcare, found the four largest pharmacy benefit managers held 75% of the national market in 2024, up from 70% in 2022. Separately, HRSA approved a 340B rebate pilot covering 10 manufacturers and 21 drugs, starting January 1, 2027.
Why it matters
Concentration among the intermediaries that set drug access and prices concentrates bargaining power. The 340B rebate model changes how safety-net providers receive discounts, and its effects on those providers are untested.
Warrants deeper follow-up. Obtain the AMA report and HRSA pilot terms; compare to prior PBM concentration estimates.
Sources
Background from our research
Storylines